Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC. Naipal KA, et al. Among authors: jonkers j. Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24. Clin Cancer Res. 2014. PMID: 24963051
Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells.
Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, Kanaar R, Berns A, Jonkers J. Loonstra A, et al. Among authors: jonkers j. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9209-14. doi: 10.1073/pnas.161269798. Proc Natl Acad Sci U S A. 2001. PMID: 11481484 Free PMC article.
How do real tumors become resistant to cisplatin?
Borst P, Rottenberg S, Jonkers J. Borst P, et al. Among authors: jonkers j. Cell Cycle. 2008 May 15;7(10):1353-9. doi: 10.4161/cc.7.10.5930. Epub 2008 Mar 17. Cell Cycle. 2008. PMID: 18418074 Review.
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J. Evers B, et al. Among authors: jonkers j. Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953. Clin Cancer Res. 2008. PMID: 18559613 Free article.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. Rottenberg S, et al. Among authors: jonkers j. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29. Proc Natl Acad Sci U S A. 2008. PMID: 18971340 Free PMC article.
Preclinical mouse models for BRCA1-associated breast cancer.
Drost RM, Jonkers J. Drost RM, et al. Among authors: jonkers j. Br J Cancer. 2009 Nov 17;101(10):1651-7. doi: 10.1038/sj.bjc.6605350. Epub 2009 Sep 29. Br J Cancer. 2009. PMID: 19904273 Free PMC article. Review.
353 results